Results released
Open the filing on sec.gov
Spero Therapeutics, Inc. (SPRO)
Nasdaq: SPRO · Pharmaceutical Preparations · Cambridge, MA · filing with the SEC since 2017
The companyfiscal 2025, as filed
Revenue$66.8M+39.2%
Net income$8.6M+112.5%
Earnings per share$0.15+111.8%
Operating cash flow-$12.6M+46.2%
Cash$40.3M-23.9%
Debtn/a
Shareholders’ equity$59.0M+28.0%
Shares, diluted59.0M+9.3%
Return on equity14.5%
The recordfrom its filings
Filings in 202640
Newest filingNov 12 · 8-K
Annual reportMar 26, 2026
Quarterly reportNov 12, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$500,000
Insider buys, 12 months$0.00
Patents granted7
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Sep 2026Revenue $41.6MNet income -$29.5MCash from operations -$40.4Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Quarterly report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Employee stock plan registration
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Registration effective
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.